Home / FINANCE / Markets Insider / BRIEF-Trovagene announces acquiescence of investigational NDA to trigger hearing of PCM-075

BRIEF-Trovagene announces acquiescence of investigational NDA to trigger hearing of PCM-075

June 27 (Reuters) – Trovagene Inc

* Trovagene announces acquiescence of investigational new drug
application to trigger proviso 1B/2 clinical hearing of PCM-075 for
acute myeloid leukemia

* Trovagene skeleton to trigger clinical trials of PCM-075 in
AML

* Have IND and custom for proviso 1B/2 clinical trial
submitted and underneath examination by FDA
Source content for Eikon:
Further association coverage:

Leave a Reply

Your email address will not be published. Required fields are marked *

*

x

Check Also

Mexico Stand-Up Pouches Market: Forecast (2017

NEW YORK, Nov. 21, 2017 /PRNewswire/ – Stand adult pouches are tangible in industrial terms as ...